AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

1. (Cancelled).

2. (Previously Presented) Crystalline oxcarbazepine, wherein the oxcarbazepine has a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta.

3. (Original) The oxcarbazepine of claim **2** having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 17.7, 19.4, 20.0, 21.1, 23.0, 24.0, 24.4 ,25.1, 26.0 ± 0.2 degrees two-theta.

4. (Original) The oxcarbazepine of claim **3** having a PXRD diffraction pattern substantially as depicted in figure 1.

5. (Previously Presented) A process for preparing the oxcarbazepine of claim **2** comprising the steps of:
   a) preparing a solution of oxcarbazepine in a mixture of dichloromethane and toluene, and
   b) evaporating the toluene and the dichloromethane leaving the oxcarbazepine as a residue.

6. (Original) The process of claim **5**, wherein the solution is prepared by dissolving oxcarbazepine in dichloromethane and adding the dichloromethane to toluene.

7. (Previously Presented) Crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta prepared by the process of claim **5**.

8. (Previously Presented) A process for preparing the oxcarbazepine of claim 2 comprising the steps of:

a) preparing a solution of oxcarbazepine in toluene;

b) heating the solution;

c) cooling the solution at a rate of 60°C min^{-1} or above to cause formation of a precipitate; and

d) separating the precipitate.

9. (Original) The process of claim **8**, wherein the solution is heated to about reflux.

10. (Original) The process of claim **8**, wherein the solution is cooled to a temperature of about 0°C.

11. (Previously Presented) Crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta prepared by the process of claim **8**.

12. (Cancelled).

13. (Previously Presented) Crystalline oxcarbazepine, wherein the oxcarbazepine has a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta.

14. (Previously Presented) The oxcarbazepine of claim **13** having a PXRD diffraction pattern with peaks at about 11.7, 17.0, 18.0, 21.7, 23.2, 24.4, 26.0 ± 0.2 degrees two-theta.

15. (Previously Presented) The oxcarbazepine of claim **14** having a PXRD diffraction pattern substantially as depicted in figure 2.

16. (Previously Presented) A process for preparing the oxcarbazepine of claim **13** comprising the steps of:

a) preparing a solution of oxcarbazepine in toluene;

b) heating the solution;

c) cooling the solution at a rate of from about 20 to 60°C $min.^{-1}$ to cause formation of a precipitate; and

d) separating the precipitate.

17. (Original) The process of claim **16**, wherein the solution is cooled at a rate of about 40°C per minute.

18. (Original) The process of claim **16**, wherein the solution is cooled to about 0°C.

19. (Original) The process of claim **16**, wherein the solution is heated to about reflux.

20. (Previously Presented) Crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta prepared by the process of claim **16**.

21. (Cancelled).

22. (Previously Presented) Crystalline oxcarbazepine, wherein the oxcarbazepine has a PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta.

23. (Previously Presented) The oxcarbazepine of claim **22** having a PXRD diffraction pattern substantially as depicted in figure 3.

24. (Previously Presented) A process for preparing the oxcarbazepine of claim **22** comprising the steps of:

a) preparing a solution of oxcarbazepine in toluene; and

b) evaporating the toluene leaving a residue of the oxcarbazepine.

25. (Original) The process of claim **24**, further comprising a step of heating the solution before evaporating.

26. (Original) The process of claim **25**, wherein the solution is heated to about reflux.

27. (Original) The process of claim **25**, further comprising cooling the heated solution before evaporating.

28. (Original) The process of claim **27**, wherein the solution is cooled to about 0°C.

29. (Original) The process of claim **24**, further comprising a step of cooling the solution.

30. (Original) The process of claim **29**, wherein the solution is cooled to about 0°C.

31. (Original) The process of claim **24**, wherein the toluene is removed from the solution by evaporation.

32. (Previously Presented) Crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta prepared by the process of claim **24**.

33. (Original) An oxcarbazepine chloroform solvate.

34. (Cancelled).

35. (Previously Presented) A crystalline oxcarbazepine chloroform solvate, wherein the oxcarbazepine has a PXRD diffraction pattern with peaks at about 14.5, 15.0, 18.2, 21.4, 22.9, 24.0, 25.8, 26.0 ± 0.2 degrees two-theta.

36. (Previously Presented) The oxcarbazepine chloroform solvate of claim **35**, wherein the oxcarbazepine has a PXRD diffraction pattern substantially as depicted in figure 4.

37. (Original) The oxcarbazepine chloroform solvate of claim **33** containing about a 27 weight % chloroform.

38. (Original) A process for preparing oxcarbazepine chloroform solvate comprising:

a) causing formation of a precipitate from a solution of oxcarbazepine in chloroform, and

b) separating the precipitate.

39. (Original) The process of claim **38**, further comprising a step of heating the solution before causing formation of the precipitate.

40. (Original) The process of claim **39**, further comprising a step of cooling the heated solution, whereby cooling causes formation of the precipitate.

41. (Original) The process of claim **39**, wherein the solution is heated to an elevated temperature of from about 50°C to about 60°C.

42. (Original) The process of claim **41**, wherein the solution is heated to an elevated temperature of about 55°C.

43. (Original) The process of claim **41**, wherein the heated solution is cooled to a reduced temperature of from about 10°C to about 20°C.

44. (Original) The process of claim **43**, wherein the reduced temperature is about 16°C.

45. (Previously Presented) The oxcarbazepine chloroform solvate produced by the process of claim **38**.

46. (Previously Presented) A process for preparing crystalline oxcarbazepine having a PXRD diffraction pattern substantially as depicted in figure 5 comprising:

a) providing the oxcarbazepine chloroform solvate of claim **35**,

b) heating the oxcarbazepine chloroform solvate, and

c) recovering the oxcarbazepine.

47. (Previously Presented) The process of claim **46**, wherein the oxcarbazepine solvate is heated to an elevated temperature in the range of from about 40°C to about 80°C.

48. (Original) The process of claim **47**, wherein the elevated temperature is about 60°C.

49. (Previously Presented) A process for preparing crystalline oxcarbazepine having a PXRD diffraction pattern substantially as depicted in figure 5 comprising

a) providing crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta,

b) heating the oxcarbazepine, and

c) recovering the oxcarbazepine.

50. (Previously Presented) The process of claim **49**, wherein the oxcarbazepine is heated to an elevated temperature in the range of from about 60°C to about 120°C.

51. (Original) The process of claim **50**, wherein the elevated temperature is about 60°C.

52. (Previously Presented) A process for the preparation of crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta comprising

a) providing crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta,

b) maintaining the oxcarbazepine at a temperature in the range of from about 20 to about 30°C, and

c) recovering the oxcarbazepine.

53. (Previously Presented) A process for preparing crystalline oxcarbazepine having a PXRD diffraction pattern substantially as depicted in figure 5 comprising:

a) contacting oxcarbazepine selected from the group consisting of crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta, and crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta with a protic solvent; and

b) recovering the oxcarbazepine.

54. (Previously Presented) The process of claim **53**, wherein the crystalline oxcarbazepine is suspended in the protic solvent.

55. (Original) The process of claim **53**, wherein the protic solvent is selected from the group consisting of water and ethanol.

56. (Previously Presented) The process of claim **54**, wherein the crystalline oxcarbazepine is suspended in the protic solvent from about two hours to about three days.

57. (Previously Presented) The process of claim **56**, wherein the crystalline oxcarbazepine is suspended for about one day.

58. (Currently Amended) A pharmaceutical composition comprising:

a) crystalline oxcarbazepine; and

b) a pharmaceutically acceptable excipient,

<u>wherein the pharmaceutical composition is a solid pharmaceutical composition and</u> wherein the crystalline oxcarbazepine is selected from the group consisting of crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta, and crystalline oxcarbazepine chloroform solvate having a PXRD diffraction pattern with peaks at about 14.5, 15.0, 18.2, 21.4, 22.9, 24.0, 25.8, 26.0 ± 0.2 degrees two-theta.

59. (Original) The pharmaceutical composition of claim **58**, wherein the composition is mixed with one or more crystalline oxcarbazepine.

60. (Original) A pharmaceutical dosage form comprising the pharmaceutical composition of claim **58**.

61. (Original) The pharmaceutical dosage form of claim **60**, wherein the dosage form is a capsule or tablet.

62. (Original) The pharmaceutical dosage form of claim **61**, wherein the dosage form is a tablet.

63. (Original) The pharmaceutical dosage form of claim **60**, containing a unit dosage of about 150mg to about 600mg oxcarbazepine.

64. (Original) The pharmaceutical dosage form of claim **63**, containing a unit dosage selected from the group consisting of about 150mg, 300mg and 600mg.

65. (Currently amended) ~~The~~ A pharmaceutical dosage form ~~of claim 60,~~ comprising a pharmaceutical composition comprising:

a) crystalline oxcarbazepine; and

b) a pharmaceutically acceptable excipient,

wherein the crystalline oxcarbazepine is selected from the group consisting of crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.9, 14.4, 20.0, 23.0, 25.1 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 21.7, 23.2, 24.4 ± 0.2 degrees two-theta, crystalline oxcarbazepine having a PXRD diffraction pattern with peaks at about 11.7, 14.2, 24.3 ± 0.2 degrees two-theta, and crystalline oxcarbazepine chloroform solvate having a PXRD diffraction pattern with peaks at about 14.5, 15.0, 18.2, 21.4, 22.9, 24.0, 25.8, 26.0 ± 0.2 degrees two-theta,

and wherein the dosage form is an oral suspension.

66. (Original) The pharmaceutical dosage form of claim **65**, wherein the dosage is about 60mg ml^{-1}.

67. (Original) The pharmaceutical dosage form of claim **66**, wherein the dosage is about 300mg ml^{-1}.

68. (Previously Presented) A method of treating a patient suffering from seizures comprising administering the pharmaceutical composition of claim **58** to a patient in need thereof.

69. (Original) The method of claim **68**, wherein the seizures are associated with epilepsy.

70. (Previously Presented) A method of treating Parkinson's disease comprising administering the pharmaceutical composition of claim **58**.

71. (Cancelled).

72. (Cancelled).

73. (New) A method of treating a patient suffering from seizures comprising administering the pharmaceutical composition of claim **65** to a patient in need thereof.

74. (New) A method of treating Parkinson's disease comprising administering the pharmaceutical composition of claim **65**.